Voya Investment Management LLC Increases Stake in Hologic, Inc. (NASDAQ:HOLX)

Voya Investment Management LLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 138,891 shares of the medical equipment provider’s stock after purchasing an additional 12,488 shares during the quarter. Voya Investment Management LLC’s holdings in Hologic were worth $10,013,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock worth $412,159,000 after buying an additional 144,838 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after buying an additional 24,358 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Hologic by 3.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock valued at $322,272,000 after acquiring an additional 129,035 shares during the last quarter. Invesco Ltd. raised its stake in shares of Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock valued at $293,434,000 after acquiring an additional 572,187 shares during the period. Finally, Boston Partners lifted its holdings in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $58.08 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1-year low of $55.89 and a 1-year high of $84.67. The business has a 50-day moving average of $60.90 and a 200-day moving average of $69.77. The company has a market capitalization of $13.03 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on HOLX shares. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Raymond James reaffirmed an “outperform” rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.